|
|
#137800
GLIOMA
OF BRAIN, FAMILIAL
Victor
A. McKusick
Alternative titles; symbols
GLIOBLASTOMA MULTIFORME,
INCLUDED; GLM, INCLUDED; GBM, INCLUDED
ASTROCYTOMA, INCLUDED
OLIGODENDROGLIOMA, INCLUDED
Gene map locus
2p22-p21,
15q23-q26.3, 10q26, 10q25.3-q26.1, 10q24, 10q23.31, 3p25
TEXT
A number sign (#) is used
with this entry because gliomas have been associated with abnormalities in
several chromosomal regions or individual genes, including GAC1 (605492)
on 1q32.1, PPARG (601487)
on 3p25, EGFR (131550)
on 7p12.3-p12.1, LGI1 (604619)
on 10q24, PTEN (601728)
on 10q23.31, GLTSCR1 (605690)
and GLTSCR2 (605691)
on 19q13.3, GAS41 (602116)
on 12q13-q15, GLI (165220)
on 12q13.2-13.3, p15 (600431)
and p16/p14 (600160)
on 9p, and loci at 15q23-q26.3 (607248),
17p13.3, and 14q.
DESCRIPTION
Gliomas are central
nervous system neoplasms derived from glial cells and comprise astrocytomas,
glioblastoma multiforme, oligodendrogliomas, and ependymomas (131445).
See also subependymomas (600139).
Gliomas are known to occur
in association with several well-defined hereditary tumor syndromes such as
neurofibromatosis-1 (NF1; 162200)
and NF2 (101000),
tuberous sclerosis (TS; 191100),
Li-Fraumeni syndrome (151623),
and Turcot syndrome (276300).
Familial clustering of gliomas often occurs in the absence of these tumor
syndromes, however.
Large germline deletions
at the INK4 (600160)
tumor suppressor region involving the p16, p15, and p14 genes have been found in
some families featuring both gliomas and skin melanomas (155755).
INHERITANCE
King
and Eisinger (1966)
described glioma multiforme of the frontal lobes in father and daughter with
development of symptoms at age 50 and 34 years, respectively. Armstrong
and Hanson (1969)
described 3 sibs who died of brain glioma in adulthood. In a study of cancer
mortality during childhood in sibs, Miller
(1971) found 8
pairs of nontwin sibs with brain tumor versus 0.9 expected. There were 8 other
families versus 0.9 expected in which 1 child died of brain tumor and another
died of cancer of bone or muscle. Thuwe
et al. (1979)
observed 6 cases of brain glioma and a possible seventh on an isolated Swedish
coastal island. The affected persons were related as cousins, all in different
sibships. One instance of parental consanguinity, the lack of parent-child
transmission, and the longtime isolation of the population suggest recessive
inheritance. In further studies in this island community, Thuwe
(1984) reported 4
closely related cases of brain tumor. It was found that 30 probands with brain
tumor were more often the product of a consanguineous marriage than were
controls and a higher proportion could be traced to a common ancestor living in
the 1600s. It was concluded that genetic factors play a role, although a single
major gene seemed unlikely. Schianchi
and Kraus-Ruppert (1980)
described affected father and son.
In a highly inbred Arab
family in Israel, Chemke
et al. (1985)
observed 5 cases of glioblastoma multiforme in 2 sibships. Curiously, all were
male and in all the tumor was located on the right side of the brain. The ages
of presentation ranged from 4 to 11 years. 'Astrocytoma type 3' was the
histologic diagnosis.
Leblanc
et al. (1986)
described father and son operated on at ages 26 and 37 years, respectively, for
mixed oligodendrocytic-astrocytic glioma. Heuch
and Blom (1986)
reported glioblastoma multiforme in 2 brothers, aged 65 and 68 years, and in
their paternal aunt, aged 81. The father had died of tuberculosis before age 40.
True multicentric origin, consistent with a hereditary basis, was observed in 1
of the 3 cases.
Tijssen
(1987) referred to
an international register of familial brain tumors maintained in Leyden. Vieregge
et al. (1987) gave
an extensive review of reported cases of familial glioma with or without other
malformations. They reported a family in which members of several generations
had one or another abnormality: father and son had glioma; another man and his
daughter had colonic polyps; and skeletal abnormalities in the form of short
stature and exostoses were present in some members. Munoz
et al. (1988)
described a brother and sister without a history of phacomatosis or cerebral
tumors who developed malignant tumors with ependymal and choroidal
differentiation. The girl presented at 28 months with a tumor of the posterior
fossa, and the boy presented at 15 months with a tumor of the left cerebral
hemisphere. Duhaime
et al. (1989)
reported histologically identical glioblastoma multiforme in 2 sibs, aged 2 and
5 years old, whose symptoms developed simultaneously.
On the basis of
segregation analyses in families with multiple glioma patients, autosomal
recessive and multifactorial mendelian models have been suggested (Malmer
et al., 2001; de
Andrade et al., 2001).
DIAGNOSIS
Marie
et al. (2001)
found that OLIG2 (606386)
expression was upregulated in neoplastic oligodendrocytes, but not in neoplastic
astrocytes or in other brain tumor cells, and suggested its use as a specific
marker in the diagnosis of oligodendroglial tumors.
Prenatal Diagnosis
The case of prenatal
diagnosis ascertained via ultrasound reported by Geraghty
et al. (1989)
illustrated the occurrence of glioblastoma multiforme in the fetus.
MAPPING
Chromosome 7
In a series of human
glioblastoma cell lines, Henn
et al. (1986)
found that the most striking and consistent chromosomal finding was an increase
in copy number of chromosome 7. In all of the cell lines, ERBB-specific mRNA
(EGFR; 131550)
was increased to levels even higher than expected from the number of chromosomes
7 present. These changes were not found in benign astrocytomas. Previously, Downward
et al. (1984)
presented evidence that oncogene ERBB may be derived from the gene coding for
EGFR.
Bigner
et al. (1988)
determined that double minute chromosomes, indicating the presence of gene
amplification, are found in about 50% of malignant gliomas. Most tumors with
double minute chromosomes contain 1 of 5 amplified genes, most often the EGFR
gene on chromosome 7. Following up on the observation that the EGFR gene is
amplified in 40% of malignant gliomas, Wong
et al. (1992)
characterized the rearrangements in 5 malignant gliomas. In one they found
deletion of most of the extracytoplasmic domain of the receptor. The 4 other
tumors had internal deletions of the gene.
Chromosome 10
Bigner
et al. (1988)
concluded that the most frequent chromosomal changes in malignant gliomas are
gains of chromosome 7 and losses of chromosome 10. Loss of 1 copy of chromosome
10 is a common event in high-grade gliomas. Rearrangement and loss of at least
some parts of the second copy, especially in the 10q23-q26 region, has been
demonstrated in approximately 80% of glioblastoma multiforme tumors (Bigner
and Vogelstein, 1990).
Chromosome 10 was
implicated in glioblastoma multiforme by Fujimoto
et al. (1989), who
found loss of constitutional heterozygosity in tumor samples from 10 of 13
patients in whom paired tumor and lymphocyte DNA samples were screened. In a
search for submicroscopic deletions in chromosome 10, Fults
and Pedone (1993)
performed a RFLP analysis in 30 patients, using markers that had been mapped
accurately on chromosome 10 by genetic linkage studies. Loss of heterozygosity
(LOH) at one or more loci was found in 15 of the 30 patients. In 7 cases, LOH
was found at every informative locus. LOH was confined to a portion of the long
arm in 6 patients; the smallest region of overlap among these 6 deletions was
flanked by markers D10S12 proximally and D10S6 distally, a 33.4-cM region mapped
physically near the telomere, 10q25.1-qter.
Karlbom
et al. (1993)
analyzed a panel of glial tumors consisting of 11 low-grade gliomas, 9
anaplastic gliomas, and 29 glioblastomas for loss of heterozygosity by examining
at least one locus for each chromosome. The frequency of allele loss was highest
among the glioblastomas, suggesting that genetic alterations accumulate during
glial tumor development. The most common genetic alteration was found to involve
allele losses of chromosome 10 loci, these being found in all glioblastomas and
in 3 anaplastic tumors. Deletion mapping analysis revealed partial loss of
chromosome 10 in 8 glioblastomas and 2 anaplastic tumors in 3 distinct regions:
one telomeric region on 1p and both telomeric and centromeric locations on 10q.
These data suggested to Karlbom
et al. (1993) the
existence of multiple chromosome 10 tumor suppressor gene loci whose
inactivation is involved in the malignant progression of glioma. In studies of
20 gliomas with microsatellite markers from chromosome 10, the locus that
exhibited the most loss (69%) was the region bordered by D10S249 and D10S558 and
inclusive of D10S594, with a linkage distance of 3 cM (Kimmelman
et al., 1996).
This region was known to be deleted in various grades of tumor, including low-
and high-grade tumors. Kimmelman
et al. (1996)
suggested that chromosome region 10p15 is involved in human gliomas of diverse
grades and that this region may harbor genes important in the development of and
progression to the malignant phenotype.
See the DMBT1 gene (601969),
so designated for 'deleted in malignant brain tumors,' for a discussion of a
gene on 10q25.3-q26.1 that showed intragenic homozygous deletions in
medulloblastoma and glioblastoma multiforme tumor tissue and in brain tumor cell
lines (Mollenhauer
et al., 1997). Chernova
et al. (1998)
isolated a novel gene on 10q24, 'leucine-rich gene, glioma-inactivated-1' (LGI1;
604619),
which was rearranged as a result of a t(10;19)(q24;q13) balanced translocation
in a glioblastoma cell line. See also the PTEN gene (601728)
on 10q23.31 in which Staal
et al. (2002)
identified a mutation in a patient with oligodendroglioma.
Chromosome 17p
El-Azouzi
et al. (1989)
described loss of constitutional heterozygosity for markers on the short arm of
chromosome 17 in both low-grade and high-grade malignant astrocytomas,
suggesting that this region may contain a tumor suppressor gene associated with
the early events in tumorigenesis. Chattopadhyay
et al. (1997)
identified a locus at 17p13.3, independent of the p53 locus, as a genetic link
in glioma tumor progression. Jin
et al. (2000)
provided further evidence of a glioma tumor suppressor gene distinct from p53 at
17p.
Chromosome 9p
Bigner
et al. (1988)
found chromosome abnormalities in 12 of 54 malignant gliomas. Structural
abnormalities of 9p and 19q were increased to a statistically significant
degree. Olopade
et al. (1992)
found molecular evidence of deletion in 9p in 10 of 15 glioma-derived cell lines
and 13 of 35 primary gliomas. The shortest region of overlap of these deletions
mapped to the interval between the centromeric end of the interferon gene
cluster and the methylthioadenosine phosphorylase locus (156540).
Simons
et al. (1999)
used representational difference analysis (RDA) of a human glioblastoma
xenograft to isolate 5 tumor-associated homozygously deleted DNA fragments, all
originating from the 9p21 region. Subsequent analysis of a series of 10
glioblastomas using the newly isolated RDA fragments in conjunction with a
series of known 9p21 DNA markers revealed homozygous deletions in 9 of the 10
tumors. These deletions encompassed the p15 (CDKN2B; 600431)
and p14/p16 (CDKN2A; 600160)
complex and 2 additional putative tumor suppressor loci. The RDA fragments
corresponded to the latter 2 loci. Taken together, these results suggested the
involvement of multiple tumor suppressor genes from the 9p21 region in
glioblastoma tumorigenesis.
Chromosomes 19 and 1
To evaluate whether loss
of chromosome 19 alleles is common in glial tumors of different types and
grades, von
Deimling et al. (1992)
performed Southern blot RFLP analysis for multiple chromosome 19 loci in 122
gliomas from 116 patients. In 29 tumors, loss of constitutional heterozygosity
of 19q was demonstrated; 4 tumors had partial deletion of 19q. The results were
interpreted as indicating the presence of a glial tumor suppressor gene on 19q.
Smith
et al. (2000)
generated a complete transcript map of a 150-kb interval of chromosome 19q13.3,
in which allelic loss is a frequent event in human diffuse gliomas, and
identified 2 novel transcripts, designated GLTSCR1 (605690)
and GLTSCR2 (605691).
Mutation analysis of the transcripts in this region in diffuse gliomas with 19q
deletions revealed no tumor-specific mutations.
Hoang-Xuan
et al. (2001)
examined the molecular profile of 26 oligodendrogliomas (10 WHO grade II and 16
WHO grade III) and found that the most frequent alterations were loss of
heterozygosity on 1p and 19q. These 2 alterations were closely associated,
suggesting that the 2 loci are involved in the same pathway of tumorigenesis. Hoang-Xuan
et al. (2001)
also found that the combination of homozygous deletion of the P16/CDKN2A tumor
suppressor gene, LOH on chromosome 10, and amplification of the EGFR oncogene
was present at a higher rate than previously reported. A statistically
significant exclusion was noted between these 3 alterations and the LOH on
1p/19q, suggesting that there are at least 2 distinct genetic subsets of
oligodendroglioma. EGFR amplification and LOH on 10q were significant predictors
of shorter progression-free survival (PFS), characterizing a more aggressive
form of tumor, whereas LOH on 1p was associated with longer PFS.
Chromosome 14q
Hu
et al. (2002)
performed allelotype analysis on 17 fibrillary astrocytomas and 21 de novo
glioblastoma multiforme and identified 2 common regions of deletions on
14q22.3-32.1 and 14q32.1-qter, suggesting the presence of 2 putative tumor
suppressor genes.
PATHOGENESIS
Von
Deimling et al. (1995)
proposed a simplified model for the pathogenesis of human gliomas. Reviewing
their work and that of others, they suggested 3 distinct pathways. The first
pathway, which leads to pilocytic astrocytomas (WHO grade I), is caused by loss
of heterozygosity for chromosome 17q, presumably unmasking mutations in the NF1
(162200)
gene. The second pathway begins with LOH at 17p, unmasking mutations in p53 (191170)
and leading to astrocytoma (WHO grade II). Further LOH at 13q, 19q and 9p,
unmasking mutations in RB1, p16 and p15, provides a further step on the second
pathway, giving rise to grade III astrocytomas. The final step on the second
pathway, LOH on chromosome 10 and perhaps other chromosomes, culminates in
glioblastoma multiforme type 1 (WHO grade IV). The third independent pathway
begins with LOH at chromosomes 10 and 9p, followed by gene amplification of
EGFR, CDK4 (123829),
MDM2 (164785),
and SAS (181035),
and culminating in glioblastoma multiforme type 2 (WHO grade IV).
MOLECULAR
GENETICS
Ueki
et al. (1997)
studied gliomas for tumor-specific alterations in the ANOVA gene (601991),
which they cloned from the glioma candidate region at 19q13.3. They found no
alterations of ANOVA in gliomas by Southern blotting and SSCP analysis,
suggesting that ANOVA is not the chromosome 19q glioma tumor suppressor gene.
Bogler
et al. (1995)
reviewed the role of the p53 tumor protein gene (191170)
in the initiation and progression of human gliomas. Tachibana
et al. (2000)
examined genomic DNA from 15 glioma patients with a family history of brain
tumors for mutations in the p53, PTEN (601728),
p16/CDKN2A (600160),
and CDK4 (123829)
genes, using direct sequencing and FISH analysis. Mutations were identified in 2
cases. A p53 germline point mutation was identified in 1 family with some
findings of Li-Fraumeni syndrome (151623),
and a hemizygous germline deletion of the p16/CDKN2A tumor suppressor region was
demonstrated in 1 family with a history of both astrocytoma and melanoma. The
authors concluded that point mutations of p53 and hemizygous deletions and other
rearrangements of the p16/CDKN2A tumor suppressor region may be responsible for
some familial glioma cases. Pollack
et al. (2002)
found that overexpression of p53 in malignant gliomas during childhood is
strongly associated with an adverse outcome, independently of clinical
prognostic factors and histologic findings.
Zhou
et al. (2000)
sought to determine if somatic high penetrance mutations in the PPAR-gamma gene
(601487)
play a role in glioblastoma multiforme. No somatic high penetrance mutations
were found in 96 patients with sporadic glioblastoma. However, polymorphisms in
this gene (601487.0002
and 601487.0010)
were overrepresented in American patients with glioblastoma, but not in German
patients.
Staal
et al. (2002)
described a 38-year-old male who presented with focal seizures of the right arm
and dysphasia in 1981. In 1985, he was found to have a meningioma (607174),
which was removed completely. A low-grade glioma of the left frontal lobe was
detected in 1990 and operated on in 1993 with subsequent radiotherapy. The tumor
was classified as an anaplastic oligodendroglioma. By 1998, regrowth of the
tumor had occurred and the diagnosis was again anaplastic oligodendroglioma. In
the patient, Staal
et al. (2002)
identified a heterozygous germline mutation of the PTEN gene (601728)
that resulted in an arg234-to-gln (R234Q; 601728.0029)
substitution, without loss of heterozygosity in tumor DNA. The patient did not
show any of the clinical signs of Cowden disease (CD; 158350)
or other hereditary diseases typically associated with PTEN germline mutations.
Hamilton
et al. (1995)
found that glioblastoma multiforme is a feature of the form of Turcot syndrome (276300)
due to defects in the mismatch repair genes MLH1 (120436)
or PMS2 (600259).
OTHER
FEATURES
Cartron
et al. (2002)
examined the expression of BAX (600040)
in 55 patients with glioblastoma multiforme. The authors identified a novel form
of BAX, designated BAX-psi, which was present in 24% of the patients. BAX-psi is
an N-terminal truncated form of BAX which results from a partial deletion of
exon 1 of the BAX gene. BAX-psi and the wildtype form, BAX-alpha, are encoded by
distinct mRNAs, both of which are present in normal tissues. Glial tumors
expressed either BAX-alpha or BAX-psi proteins, an apparent consequence of an
exclusive transcription of the corresponding mRNAs. The BAX-psi protein was
preferentially localized to mitochondria and was a more powerful inducer of
apoptosis than BAX-alpha. BAX-psi tumors exhibited slower proliferation in Swiss
nude mice, and this feature could be circumvented by the coexpression of the
BCL2 (151430)
transgene, the functional antagonist of BAX. The expression of BAX-psi
correlated with a longer survival in patients (18 months versus 10 months for
BAX-alpha patients). The authors hypothesized a beneficial involvement of the
psi variant of BAX in tumor progression.
ANIMAL MODEL
Holland
et al. (2000)
transferred, in a tissue-specific manner, genes encoding activated forms of Ras
(190070)
and Akt (164730)
to astrocytes and neural progenitors in mice. They found that although neither
activated Ras nor Akt alone was sufficient to induce glioblastoma multiforme
formation, the combination of activated Ras and Akt induced high-grade gliomas
with the histologic features of human GBMs. These tumors appeared to arise after
gene transfer to neural progenitors, but not after transfer to differentiated
astrocytes. Increased activity of RAS is found in many human GBMs, and Holland
et al. (2000)
demonstrated that AKT activity is increased in most of these tumors, implying
that combined activation of these 2 pathways accurately models the biology of
this disease.
Gutmann
et al. (2002)
generated a transgenic mouse model that targeted an activated Ras molecule to
astrocytes, resulting in high-grade astrocytoma development in 3 to 4 months.
They used high-density oligonucleotide arrays to perform gene expression
profiling on cultured wildtype mouse astrocytes, non-neoplastic transgenic
astrocytes, and neoplastic astrocytes. The authors identified changes in
different groups of genes, including those associated with cell adhesion and
cytoskeleton-mediated processes, astroglial-specific genes, growth regulation
and, in particular, a reduced expression of GAP43 (162060),
suggesting that it regulates growth in astrocytes.
SEE ALSO
Bigner
et al. (1988); de
Tribolet et al. (1979); Haley
et al. (1969); Isamat
et al. (1974); Kjellin
et al. (1960);
Koch
and Waldbaur (1981);
Parkinson
and Hall (1962); Reese
et al. (1944); Von
Motz et al. (1977)
REFERENCES
1. Armstrong, R. M.; Hanson, C. W. :
Familial
gliomas. Neurology
19: 1061-1063,
1969.
PubMed ID : 5388073
2. Bigner, S. H.; Mark, J.; Burger, P. C.; Mahaley, M. S., Jr.; Bullard,
D. E.; Muhlbaier, L. H.; Bigner, D. D. :
Specific
chromosomal abnormalities in malignant human gliomas. Cancer
Res. 88: 405-411, 1988.
3.
Bigner, S. H.; Vogelstein, B. :
Cytogenetics
and molecular genetics of malignant gliomas and medulloblastoma. Brain
Path. 1: 12-18, 1990.
4.
Bigner, S. H.; Vogelstein, B.; Bigner, D. D. :
Chromosomal
abnormalities and gene amplification in malignant gliomas. Atlas Sci. Biochem. 333-336, 1988.
5.
Bogler, O.; Huang, H.-J. S.; Kleihues, P.; Cavenee, W. K. :
The
p53 gene and its role in human brain tumors. GLIA 15:
308-327, 1995.
PubMed ID : 8586466
6. Cartron, P.-F.; Oliver, L.; Martin, S.; Moreau, C.; LeCabellec, M.-T.;
Jezequel, P.; Meflah, K.; Vallette, F. M. :
The
expression of a new variant of the pro-apoptotic molecule Bax, Bax-psi, is
correlated with an increased survival of glioblastoma multiforme patients. Hum.
Molec. Genet. 11:
675-687, 2002.
PubMed ID : 11912183
7. Chattopadhyay, P.; Rathore, A.; Mathur, M.; Sarkar, C.; Mahapatra, A.
K.; Sinha, S. :
Loss
of heterozygosity of a locus on 17p13.3, independent of p53, is associated with
higher grades of astrocytic tumours. Oncogene
15: 871-874,
1997.
PubMed ID : 9266974
8. Chemke, J.; Katznelson, D.; Zucker, G. :
Familial
glioblastoma multiforme without neurofibromatosis. Am. J. Med. Genet. 21: 731-735, 1985.
PubMed ID : 2992272
9. Chernova, O. B.; Somerville, R. P. T.; Cowell, J. K. :
A
novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain
tumors. Oncogene
17: 2873-2881,
1998.
PubMed ID : 9879993
10. de Andrade, M.; Barnholtz, J. S.; Amos, C. I.; Adatto, P.; Spencer,
C.; Bondy, M. L. :
Segregation
analysis of cancer in families of glioma patients. Genet.
Epidemiol. 20:
258-270, 2001.
PubMed ID : 11180451
11.
de Tribolet, N.; Deruaz, J.-P.; Zander, E. :
Familial
gliomas. Neurochirurgia
22: 225-228,
1979.
PubMed ID : 229433
12. Downward, J.; Yarden, Y.; Mayes, E.; Scrace, G.; Totty, N.;
Stockwell, P.; Ullrich, A.; Schlessinger, J.; Waterfield, M. D. :
Close
similarity of epidermal growth factor receptor and v-erb-B oncogene protein
sequences. Nature
307: 521-527,
1984.
PubMed ID : 6320011
13. Duhaime, A. C.; Bunin, G.; Sutton, L.; Rorke, L. B.; Packer, R. J. :
Simultaneous
presentation of glioblastoma multiforme in siblings two and five years old: case
report. Neurosurgery
24: 434-439,
1989.
PubMed ID : 2538772
14. El-Azouzi, M.; Chung, R. Y.; Farmer, G. E.; Martuza, R. L.; Black, P.
M.; Rouleau, G. A.; Hettlich, C.; Hedley-Whyte, E. T.; Zervas, N. T.;
Panagopoulos, K.; Nakamura, Y.; Gusella, J. F.; Seizinger, B. R. :
Loss
of distinct regions on the short arm of chromosome 17 associated with
tumorigenesis of human astrocytomas. Proc.
Nat. Acad. Sci. 86:
7186-7190, 1989.
PubMed ID : 2571151
15. Fujimoto, M.; Fults, D. W.; Thomas, G. A.; Nakamura, Y.; Heilbrun, M.
P.; White, R.; Story, J. L.; Naylor, S. L.; Kagan-Hallet, K. S.; Sheridan, P. J.
:
Loss
of heterozygosity on chromosome 10 in human glioblastoma multiforme. Genomics
4: 210-214, 1989.
PubMed ID : 2544511
16. Fults, D.; Pedone, C. :
Deletion
mapping of the long arm of chromosome 10 in glioblastoma multiforme. Genes
Chromosomes Cancer 7:
173-177, 1993.
PubMed ID : 7687872
17. Geraghty, A. V.; Knott, P. D.; Hanna, H. M. :
Prenatal diagnosis of fetal
glioblastoma multiforme. Prenatal Diag. 9: 613-616, 1989.
PubMed ID : 2552427
18. Gutmann, D. H.; Huang, Z.; Hedrick, N. M.; Ding, H.; Guha, A.;
Watson, M. A. :
Mouse
glioma gene expression profiling identifies novel human glioma-associated genes.
Ann. Neurol. 51:
393-405, 2002.
PubMed ID : 11891838
19. Haley, J.; Whittle, N.; Bennett, P.; Kinchington, D.; Ullrich, 1.
Armstrong, R. M.; Hanson, C. W. :
Familial
gliomas. Neurology
19: 1061-1063,
1969.
PubMed ID : 5388073
20. Hamilton, S. R.; Liu, B.; Parsons, R. E.; Papadopoulos, N.; Jen, J.;
Powell, S. M.; Krush, A. J.; Berk, T.; Cohen, Z.; Tetu, B.; Burger, P. C.; Wood,
P. A.; Taqi, F.; Booker, S. V.; Petersen, G. M.; Offerhaus, G. J. A.; Tersmette,
A. C.; Giardiello, F. M.; Vogelstein, B.; Kinzler, K. W. :
The
molecular basis of Turcot's syndrome. New
Eng. J. Med. 332:
839-847, 1995.
PubMed ID : 7661930
21.
Henn, W.; Blin, N.; Zang, K. D. :
Polysomy
of chromosome 7 is correlated with overexpression of the erbB oncogene in human
glioblastoma cell lines. Hum.
Genet. 74:
104-106, 1986.
PubMed ID : 3759084
22.
Heuch, I.; Blom, G. P. :
Glioblastoma
multiforme in three family members, including a case of true multicentricity. J.
Neurol. 233:
142-144, 1986.
PubMed ID : 3014072
23.
Hoang-Xuan, K.; He, J.; Huguet, S.; Mokhtari, K.; Marie, Y.; Kujas, M.; Leuraud,
P.; Capelle, L.; Delattre, J. Y.; Poirier, J.; Broet, P.; Sanson, M. :
Molecular
heterogeneity of oligodendrogliomas suggests alternative pathways in tumor
progression. Neurology
57: 1278-1281,
2001.
PubMed ID : 11591848
24. Holland, E. C.; Celestino, J.; Dai, C.; Schaefer, L.; Sawaya, R. E.;
Fuller, G. N. :
Combined
activation of Ras and Akt in neural progenitors induces glioblastoma formation
in mice. Nature
Genet. 25: 55-57,
2000.
PubMed ID : 10802656
25. Hu, J.; Pang, J. C.; Tong, C. Y.; Lau, B.; Yin, X.-I.; Poon, W.-S.;
Jiang, C.-C.; Zhou, L.-F.; Ng, H.-K. :
High-resolution
genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent
genetic alteration in astrocytic tumours. Brit. J. Cancer 87: 218-224, 2002.
PubMed ID : 12107846
26.
Isamat, F.; Miranda, A. M.; Bartumeus, F.; Prat, J. :
Genetic
implications of familial brain tumors. J.
Neurosurg. 41:
573-575, 1974.
PubMed ID : 4424633
27. Jin, W.; Xu, X.; Yang, T.; Hua, Z. :
p53
mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10,
17p in human gliomas. Chin.
Med. J. 113:
662-666, 2000.
PubMed ID : 11776043
28. Karlbom, A. E.; James, C. D.; Boethius, J.; Cavenee, W. K.; Collins,
V. P.; Nordenskjold, M.; Larsson, C. :
Loss
of heterozygosity in malignant gliomas involves at least three distinct regions
on chromosome 10. Hum.
Genet. 92:
169-174, 1993.
PubMed ID : 8370584
29. Kimmelman, A. C.; Ross, D. A.; Liang, B. C. :
Loss
of heterozygosity of chromosome 10p in human gliomas. Genomics
34: 250-254,
1996.
PubMed ID : 8661060
30. King, A. B.; Eisinger, G. :
May
glioma multiforme be hereditary? Guthrie
Clin. Bull. 35:
169-175, 1966.
31. Kjellin, K.; Muller, R.; Astrom, K. E. :
The
occurrence of brain tumor in several members of a family. J. Neuropath. Exp. Neurol. 19: 528-537, 1960.
32.
Koch, G.; Waldbaur, H. :
Erbliche
Hirngeschwuelste (brain tumour family syndrome). Z.
Allg. Med. 57:
1219-1224, 1981.
33.
Leblanc, R.; Lozano, A.; Robitaille, Y. :
Familial
mixed oligodendrocytic-astrocytic gliomas. Neurosurgery
18: 480-482,
1986.
PubMed ID : 3703224
34. Malmer, B.; Iselius, L.; Holmberg, E.; Collins, A.; Henriksson, R.;
Gronberg, H. :
Genetic
epidemiology of glioma. Brit.
J. Cancer 84:
429-234, 2001.
PubMed ID : 11161412
35.
Marie, Y.; Sanson, M.; Mokhtari, K.; Leuraud, P.; Kujas, M.; Delattre, J.-Y.;
Poirier, J.; Zalc, B.; Hoang-Xuan, K. :
OLIG2
as a specific marker of oligodendroglial tumour cells. Lancet
358: 298-300,
2001.
PubMed ID : 11498220
36. Miller, R. W. :
Deaths
from childhood leukemia and solid tumors among twins and other sibs in the
United States, 1960-67. J.
Nat. Cancer Inst. 46:
203-209, 1971.
37.
Mollenhauer, J.; Wiemann, S.; Scheurlen, W.; Korn, B.; Hayashi, Y.; Wilgenbus,
K. K.; van Deimling, A.; Poustka, A. :
DMBT1,
a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in
malignant brain tumours. Nature
Genet. 17: 32-39,
1997.
PubMed ID : 9288095
38.
Munoz, D. G.; Griebel, R.; Rozdilsky, B.; George, D. :
Cerebral
malignant tumors with ependymal and choroidal differentiation in two siblings. Neurosurgery
22: 928-933,
1988.
PubMed ID : 3380285
39. Olopade, O. I.; Jenkins, R. B.; Ransom, D. T.; Malik, K.; Pomykala,
H.; Nobori, T.; Cowan, J. M. :
Rowley,
J. D. and Diaz, M. O.: Molecular analysis of deletions of the short arm of
chromosome 9 in human gliomas. Cancer
Res. 52:
2523-2529, 1992.
PubMed ID : 1568221
40. Parkinson, D.; Hall, C. W. :
Oligodendrogliomas:
simultaneous appearance in frontal lobes in siblings. J. Neurosurg. 19: 424-426, 1962.
41. Pollack, I. F.; Finkelstein, S. D.; Woods, J.; Burnham, J.; Holmes,
E. J.; Hamilton, R. L.; Yates, A. J.; Boyett, J. M.; Finlay, J. L.; Sposto, R. :
Expression
of p53 and prognosis in children with malignant gliomas. New Eng. J. Med. 346: 420-427, 2002.
PubMed ID : 11832530
42. Reese, W.; Meredith, J. M.; Zfass, I. S. :
Cerebral glioma in siblings. Sth.
Med. J. 37:
424-428, 1944.
43.
Schianchi, P.; Kraus-Ruppert, R. :
Familial
brain tumors: rhombencephalon-astrocytoma grade I in father and son. Acta Neuropath. 52: 153-155, 1980.
PubMed ID : 7435166
44. Simons, A.; Jeuken, J. W. M.; Eleveld, M. J.; Boerman, R. H.; Geurts
van Kessel, A. :
:Isolation
and characterization of glioblastoma-associated homozygously deleted DNA
fragments from chromosomal region 9p21 suggests involvement of multiple tumour
suppressor genes. J.
Path. 189:
402-409, 1999.
PubMed ID : 10547603
45. Smith, J. S.; Tachibana, I.; Pohl, U.; Lee, H. K.; Thanarajasingam,
U.; Portier, B. P.; Ueki, K.; Ramaswamy, S.; Billings, S. J.; Mohrenweiser, H.
W.; Louis, D. N.; Jenkins, R. B. :
A
transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics
64: 44-50, 2000.
PubMed ID : 10708517
46. Staal, F. J. T.; van der Luijt, R. B.; Baert, M. R. M.; van Drunen,
J.; van Bakel, H.; Peters, E.; de Valk, I.; van Amstel, H. K. P.; Taphoorn, M.
J. B.; Jansen, G. H.; van Veelen, C. W. M.; Burgering, B.; Staal, G. E. J. :
A
novel germline mutation of PTEN associated with brain tumours of multiple
lineages. Brit.
J. Cancer 86:
1586-1591, 2002.
PubMed ID : 12085208
47. Tachibana, I.; Smith, J. S.; Sato, K.; Hosek, S. M.; Kimmel, D. W.;
Jenkins, R. B. :
Investigation
of germline PTEN, p53, p16-INK4A/p14-ARF, and CDK4 alterations in familial
glioma. Am. J. Med. Genet.
92: 136-141,
2000.
PubMed ID : 10797439
48. Thuwe, I. :
Glioma
cerebri in an island community. Sweden:
St Jorgen's Hospital, Univ. of Goteberg (pub.) 1984.
49.
Thuwe, I.; Lundstrom, B.; Walinder, J. :
Familial
brain tumour. (Letter)
Lancet I: 504 only, 1979.
PubMed ID : 85100
50.
Tijssen, C. C. :
Familial
mixed oligodendrocytic-astrocytic gliomas. (Letter)
Neurosurgery 20: 62 only, 1987.
PubMed ID : 3808277
51. Ueki, K.; Ramaswamy, S.; Billings, S. J.; Mohrenweiser, H. W.; Louis,
D. N. :
ANOVA,
a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3. Neurogenetics
1: 31-36, 1997.
PubMed ID : 10735272
52.
Vieregge, P.; Gerhard, L.; Nahser, H. C. :
Familial
glioma: occurrence within the 'familial cancer syndrome' and systemic
malformations. J.
Neurol. 234:
220-232, 1987.
PubMed ID : 3612193
53.
von Deimling, A.; Louis, D. N.; von Ammon, K.; Petersen, I.; Wiestler, O. D.;
Seizinger, B. R. :
Evidence
for a tumor suppressor gene on chromosome 19q associated with human
astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer
Res. 52:
4277-4279, 1992.
PubMed ID : 1353411
54.
von Deimling, A.; Louis, D. N.; Wiestler, O. D. :
Molecular
pathways in the formation of gliomas. GLIA 15: 328-338,
1995.
PubMed ID : 8586467
55.
Von Motz, I. P.; Bots, G. T. A. M.; Endtz, L. J. :
Astrocytoma
in three sisters. Neurology
27: 1038-1041,
1977.
PubMed ID : 562999
56.
Wong, A. J.; Ruppert, J. M.; Bigner, S. H.; Grzeschik, C. H.; Humphrey, P. A.;
Bigner, D. S.; Vogelstein, B. :
Structural
alterations of the epidermal growth factor receptor gene in human gliomas. Proc.
Nat. Acad. Sci. 89:
2965-2969, 1992.
PubMed ID : 1557402
57. Zhou, X.-P.; Smith, W. M.; Gimm, O.; Mueller, E.; Gao, X.; Sarraf,
P.; Prior, T. W.; Plass, C.; van Deimling, A.; Black, P. M.; Yates, A. J.; Eng,
C. :
Over-representation
of PPAR-gamma sequence variants in sporadic cases of glioblastoma multiforme:
preliminary evidence for common low penetrance modifiers for brain tumour risk
in the general population. J.
Med. Genet. 37:
410-414, 2000.
PubMed ID : 10851250
CONTRIBUTORS
Cassandra L. Kniffin -
updated : 12/6/2002
Cassandra L. Kniffin - updated : 11/13/2002
George E. Tiller - updated : 10/17/2002
Cassandra L. Kniffin - reorganized : 9/26/2002
Cassandra L. Kniffin - updated : 9/26/2002
Victor A. McKusick - updated : 8/23/2002
Cassandra L. Kniffin - updated : 5/29/2002
Victor A. McKusick - updated : 2/28/2002
Michael J. Wright - updated : 7/23/2001
Sonja A. Rasmussen - updated : 10/12/2000
Ada Hamosh - updated : 4/28/2000
Victor A. McKusick - updated : 1/19/2000
Orest Hurko - updated : 4/6/1998
Victor A. McKusick - updated : 9/12/1997
Victor A. McKusick - updated : 9/2/1997
CREATION DATE
Victor A. McKusick :
6/4/1986
EDIT HISTORY
carol : 5/16/2003
cwells : 12/9/2002
ckniffin : 12/6/2002
tkritzer : 12/2/2002
cwells : 11/26/2002
ckniffin : 11/13/2002
cwells : 10/17/2002
ckniffin : 10/3/2002
carol : 9/26/2002
carol : 9/26/2002
ckniffin : 9/20/2002
mgross : 8/23/2002
carol : 6/3/2002
ckniffin : 5/29/2002
cwells : 5/29/2002
cwells : 3/1/2002
terry : 2/28/2002
alopez : 7/27/2001
terry : 7/23/2001
terry : 6/4/2001
mcapotos : 10/13/2000
mcapotos : 10/12/2000
alopez : 5/1/2000
terry : 4/28/2000
mcapotos : 1/21/2000
terry : 1/19/2000
carol : 12/17/1998
carol : 6/22/1998
terry : 4/6/1998
terry : 9/12/1997
jenny : 9/3/1997
terry : 9/2/1997
mark : 2/18/1997
terry : 2/6/1997
terry : 6/26/1996
terry : 6/21/1996
mark : 3/26/1996
terry : 3/21/1996
mark : 5/15/1995
mimadm : 9/24/1994
terry : 4/27/1994
pfoster : 2/18/1994
carol : 11/12/1993
carol : 10/29/1993
Copyright © 1966-2003
Johns Hopkins University
Source: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=137800
|
